Horizon Therapeutics plc has reached the blockbuster big leagues with the launch of Tepezza (teprotumumab) for thyroid eye disease. It became the breakout launch of 2020 even in the challenging environment caused by COVID-19 and the strength of the franchise is poised to position Horizon as a credible rare disease specialist – even though the pandemic created a supply issue.
Tepezza generated $820m in 2020 after launching that February for the rare eye condition, putting it among the best drug...
